New Frontiers in Oncolytic Viruses: Optimizing and Selecting for Virus Strains with Improved Efficacy

Overview

Journal Biologics

Date 2018 Feb 16

PMID 29445265

Citations 21

Authors

Kenneth Lundstrom

Affiliations

Soon will be listed here.

Abstract

Oncolytic viruses have demonstrated selective replication and killing of tumor cells. Different types of oncolytic viruses - adenoviruses, alphaviruses, herpes simplex viruses, Newcastle disease viruses, rhabdoviruses, Coxsackie viruses, and vaccinia viruses - have been applied as either naturally occurring or engineered vectors. Numerous studies in animal-tumor models have demonstrated substantial tumor regression and prolonged survival rates. Moreover, clinical trials have confirmed good safety profiles and therapeutic efficacy for oncolytic viruses. Most encouragingly, the first cancer gene-therapy drug - Gendicine, based on oncolytic adenovirus type 5 - was approved in China. Likewise, a second-generation oncolytic herpes simplex virus-based drug for the treatment of melanoma has been registered in the US and Europe as talimogene laherparepvec.

Citing Articles

Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis.

Zhao J, Lin B, Luo C, Yi Y, Huang P, Chen Y J Transl Med. 2024; 22(1):1000.

PMID: 39501324 PMC: 11539571. DOI: 10.1186/s12967-024-05794-4.

Glutathione affinity chromatography for the scalable purification of an oncolytic virus immunotherapy from microcarrier cell culture.

Swartz A, Shieh Y, Gulasarian A, Curtis E, Hofmann C, Baker J Front Bioeng Biotechnol. 2023; 11:1193454.

PMID: 37397964 PMC: 10310922. DOI: 10.3389/fbioe.2023.1193454.

Apoptotic and autophagic cell death induced in cervical cancer cells by a dual specific oncolytic adenovirus.

Li S, Li Z, Chen S, Zhu Y, Li Y, Yin X Anticancer Drugs. 2023; 34(3):361-372.

PMID: 36730009 PMC: 9891282. DOI: 10.1097/CAD.0000000000001452.

Selective modulation of cell surface proteins during vaccinia infection: A resource for identifying viral immune evasion strategies.

Depierreux D, Altenburg A, Soday L, Fletcher-Etherington A, Antrobus R, Ferguson B PLoS Pathog. 2022; 18(6):e1010612.

PMID: 35727847 PMC: 9307158. DOI: 10.1371/journal.ppat.1010612.

Electrical Stimulation for Immune Modulation in Cancer Treatments.

Das R, Langou S, Le T, Prasad P, Lin F, Nguyen T Front Bioeng Biotechnol. 2022; 9:795300.

PMID: 35087799 PMC: 8788921. DOI: 10.3389/fbioe.2021.795300.

References

Cassel W, Murray D . A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother. 1992; 9(4):169-71. DOI: 10.1007/BF02987752. View

Chernichenko N, Linkov G, Li P, Bakst R, Chen C, He S . Oncolytic vaccinia virus therapy of salivary gland carcinoma. JAMA Otolaryngol Head Neck Surg. 2013; 139(2):173-82. PMC: 4413455. DOI: 10.1001/jamaoto.2013.1360. View

Slovin S, Kehoe M, Durso R, Fernandez C, Olson W, Gao J . A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine. 2012; 31(6):943-9. DOI: 10.1016/j.vaccine.2012.11.096. View

Huang J, Zhang S, Choi K, Choi I, Kim J, Lee M . Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther. 2009; 18(2):264-74. PMC: 2839296. DOI: 10.1038/mt.2009.205. View

Kaufman H, Kohlhapp F, Zloza A . Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015; 14(9):642-62. PMC: 7097180. DOI: 10.1038/nrd4663. View

Zhou Y, Wen F, Zhang P, Tang R, Li Q . Vesicular stomatitis virus is a potent agent for the treatment of malignant ascites. Oncol Rep. 2015; 35(3):1573-81. DOI: 10.3892/or.2015.4522. View

Verheije M, Rottier P . Retargeting of viruses to generate oncolytic agents. Adv Virol. 2012; 2012:798526. PMC: 3265223. DOI: 10.1155/2012/798526. View

Steiner H, Bonsanto M, Beckhove P, Brysch M, Geletneky K, Ahmadi R . Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol. 2004; 22(21):4272-81. DOI: 10.1200/JCO.2004.09.038. View

Fountzilas C, Patel S, Mahalingam D . Review: Oncolytic virotherapy, updates and future directions. Oncotarget. 2017; 8(60):102617-102639. PMC: 5731986. DOI: 10.18632/oncotarget.18309. View

10.

Gulley J, Heery C, Madan R, Walter B, Merino M, Dahut W . Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol Immunother. 2013; 62(9):1521-31. PMC: 6351424. DOI: 10.1007/s00262-013-1448-0. View

11.

Ehrig K, Kilinc M, Chen N, Stritzker J, Buckel L, Zhang Q . Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68. J Transl Med. 2013; 11:79. PMC: 3621142. DOI: 10.1186/1479-5876-11-79. View

12.

Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S . Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol. 2005; 79(9):5414-20. PMC: 1082737. DOI: 10.1128/JVI.79.9.5414-5420.2005. View

13.

Crommentuijn M, Kantar R, Noske D, Vandertop W, Badr C, Wurdinger T . Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. Mol Ther Oncolytics. 2016; 3:16017. PMC: 4916948. DOI: 10.1038/mto.2016.17. View

14.

Patel D, Foreman P, Nabors L, Riley K, Gillespie G, Markert J . Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Hum Gene Ther Clin Dev. 2016; 27(2):69-78. PMC: 4932657. DOI: 10.1089/humc.2016.031. View

15.

Au G, Lincz L, Enno A, Shafren D . Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol. 2007; 137(2):133-41. DOI: 10.1111/j.1365-2141.2007.06550.x. View

16.

Uhlig K, Schulke S, Scheuplein V, Malczyk A, Reusch J, Kugelmann S . Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response. J Virol. 2015; 89(17):9044-60. PMC: 4524058. DOI: 10.1128/JVI.00844-15. View

17.

Brun J, Mahoney D, Le Boeuf F, Lefebvre C, Sanaei C, Falls T . Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum. Int J Cancer. 2012; 132(3):726-31. DOI: 10.1002/ijc.27695. View

18.

Gomella L, Mastrangelo M, McCue P, Maguire HC J, Mulholland S, Lattime E . Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol. 2001; 166(4):1291-5. View

19.

Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y . Decorin gene upregulation mediated by an adeno-associated virus vector increases intratumoral uptake of nab-paclitaxel in neuroblastoma via inhibition of stabilin-1. Invest New Drugs. 2017; 35(5):566-575. DOI: 10.1007/s10637-017-0477-5. View

20.

Mastrangelo M, Lattime E . Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther. 2003; 9(12):1013-21. DOI: 10.1038/sj.cgt.7700538. View